Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The NHS is to expand the use of the OpenSAFELY research platform, behind the roll-out of new Covid-19 treatments, to help drive life-saving advances for other major diseases.

NHS England’s OpenSAFELY service was developed in collaboration with the Bennett Institute for Applied Data Science within the Nuffield Department of Primary Care Health Sciences, at the University of Oxford. 

With the support of GPs and academic researchers, the NHS is widening the use of the service to allow scientists to securely analyse data in GP systems – without seeing patient-identifiable information – in a plan which could lead to the discovery of new treatments for other major conditions such as cancer,
diabetes and asthma.

Access to this data will help researchers understand more about medicines,
treatments and patient outcomes, which could support better clinical practice and provide crucial evidence on the most effective prescribing.

During the pandemic, academic researchers used anonymised NHS data to help
identify new treatments for Covid-19 and understand how best to keep communities safe. Data analysis also helped the NHS to prioritise care to the most vulnerable people, and to develop vaccines against the virus.

One of the key systems used to deliver these insights was
OpenSAFELY – which has so far enabled over 150 research projects from 22 different organisations. It played a crucial role during the pandemic, helping researchers to understand which patients were most at risk from the virus, evaluate the effectiveness of vaccines, monitor which patients were receiving new Covid-19 treatments, and understand changes in patient care during and after the pandemic.

The NHS will now carefully test which types of research the service could support beyond Covid-19, following feedback from academic researchers, patients, and medical professionals.

OpenSAFELY is designed to keep patient data confidential and secure, and the de-identified data does not leave the platform at any stage. Researchers write the code for their analyses without directly accessing patient data, and their queries are then submitted for automatic analysis against patient records inside a secure setting that no researcher ever needs to access. Only anonymised results are released from the platform, following output checks. 

will be open to new research applicants as soon as possible in 2024.

Professor Ben
, Director of the Bennett Institute for Applied Data Science within the Nuffield Department of Primary Care Health Sciences, University of Oxford
'OpenSAFELY has shown that it’s possible to address privacy concerns, and also deliver research outputs at scale, in collaboration with our diverse community of analyst users across the country. We are excited to be working ever more closely with NHS England on this important service.'

NHS National Medical Director for Transformation Dr
Vin Diwakar
, said
'The data held by the NHS is globally unique and as we saw during the pandemic, this approach enables researchers to benefit from that valuable resource, whilst keeping the data secure, safe and private. 

Expanding this service will unlock the power of patient data to help drive life-saving treatment breakthroughs to help people with a range of conditions and illnesses.'

Health and Social Care Secretary, Victoria Atkins
, said
'Our NHS is at the forefront of life-saving medical research, and services like this will help drive future breakthroughs that deliver the best outcomes for patients. It played a vital role during the pandemic, helping us to identify which people were most at risk of the virus and determine the effectiveness of vaccines. 

I am determined that we now build on this progress. By using patient data while protecting their privacy, we will be able to support people with a range of conditions including cancer, diabetes and asthma – encouraging innovation and life-saving research.'

Drs Mark Coley, Paul Atkinson and Imran Khan, co-chairs and vice-chair of the BMA and RCGP’s Joint GP IT Committee
, said
'The Committee has witnessed how the
OpenSAFELY platform, and the services run by the OpenSAFELY team, have matured to become a valuable component of NHS analysis infrastructure, with associated benefits for patients and the NHS, whilst supporting patient privacy and transparency of research. The Committee therefore supports the use of the OpenSAFELY service to extend to approved research analyses beyond Covid-19.'

Bacon, Chief Technical Officer of the Bennett Institute for Applied Data Science, within the Nuffield Department of Primary Care Health Sciences, University of Oxford, said
'The OpenSAFELY platform is a groundbreaking framework for reproducible, safe, open science. NHS England’s commitment to the software and service will support its continued growth, and expand its relevance for the wider open science community.'

Professor Laurie Tomlinson, from the London School of Hygiene and Tropical Medicine,
'As a clinician who has worked with Electronic Health Record data for many years, it has been frustrating to see that the potential of NHS patient data to improve care and health service delivery has been largely untapped. OpenSAFELY is a transformative approach to patient data, enabling rapid, large-scale research to provide answers to critically important research questions, while protecting patient privacy. I am absolutely delighted that it has become part of the national infrastructure for the secure use of patient records to improve healthcare.'


Contact our communications team

Opinions expressed are those of the authors and not of Oxford University. Readers' comments will be moderated - see our guidelines for further information.